Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 87
Filter
3.
Transpl Immunol ; 9(1): 43-9, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11680571

ABSTRACT

OBJECTIVE: The macrolide immunosuppressant RAD and the immunomodulator FTY720 have distinct mechanisms ofaction. We investigated the efficacy of RAD (everolimus, certican) alone or in combination with FTY720 on graft survival (GS)and histology in comparison with CsA, using mouse strains with strong MHC disparity. METHODS: Heterotopic cardiac grafting was performed using the C57B1/6 to C3H strain combination. Osmotic mini-pumps filled with CsA or RAD were implanted subcutaneously. IFTY720 was administered as a single daily dose by gavage. Peripheral lymphocyte count (PLC) was determined at 1, 4 and 8 weeks or on the day of sacrifice. Body weight was recorded on the day of surgery and weekly. Grafts were histologically evaluated. MAIN FINDINGS: In placebo-treated mice the allografts were rejected after 7 days. Monotherapy with 10 and 30 mg/kg/day CsA achieved 10 and 22.5 days median survival time (MST), while 0.1, 0.3, 1 and 3 mg/kg/day RAD resulted in 10.5, 20, > 56 and > 56 days MST, respectively. FTY720 lowered the PLC significantly, while the lower CsA dose and RAD did not influence the PLC. Adding FTY720 to the 0.6 mg/kg/day dose of RAD extended GS modestly but reduced significantly the perivascular infiltration and endothelialitis in the grafts compared with RAD monotherapy. CONCLUSIONS: Underthe conditions of the present experiment RAD was more potent than CsA in extending the GS. Combining FTY720 and RADwas well tolerated with respect to weight gain and lack of clinically detectable infections in the mice. The 2-drug regimens suppressed the inflammatory allo-response better than RAD monotherapy.


Subject(s)
Cyclosporine/therapeutic use , Graft Rejection/prevention & control , Heart Transplantation , Immunosuppressive Agents/therapeutic use , Sirolimus/therapeutic use , Animals , Arteritis/pathology , Arteritis/prevention & control , Cyclosporine/administration & dosage , Drug Evaluation, Preclinical , Drug Therapy, Combination , Endothelium, Vascular/pathology , Everolimus , Female , Graft Rejection/pathology , Graft Survival/drug effects , Heart Transplantation/immunology , Heart Transplantation/pathology , Immunosuppressive Agents/administration & dosage , Infusion Pumps, Implantable , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Myocardium/pathology , Sirolimus/administration & dosage , Sirolimus/analogs & derivatives , Transplantation, Homologous/immunology
4.
Transplantation ; 72(1): 168-71, 2001 Jul 15.
Article in English | MEDLINE | ID: mdl-11468555

ABSTRACT

BACKGROUND: FTY720 lowers the peripheral lymphocyte count (PLC) by accelerating the migration of circulating lymphocytes to secondary lymphoid organs. We investigated the efficacy of combined FTY720+cyclosporine (CsA) treatment versus monotherapy on prolonging graft survival and on lowering the PLC. METHODS: BALB/c hearts were heterotopically grafted in C3H mice. FTY720 was administered alone or in combination with CsA. PLC and body weight were determined on day 7, day 28, or the day of rejection. RESULTS: Combining FTY720 with CsA prolonged, dose-dependently and significantly, the allograft survival. FTY720, but not CsA, lowered the PLC dose-dependently. The granulocyte count was not reduced in any group. FTY720 concentrations were not influenced by the CsA co-administration. CONCLUSIONS: Combined FTY720 and CsA treatment was well tolerated, promoted graft survival, and suppressed the inflammatory allo-response. The PLC lowering correlated well with the antirejection effects in the two-drug regimens, suggesting that the PLC might guide FTY720 therapy at low doses.


Subject(s)
Cyclosporine/pharmacology , Graft Survival/drug effects , Heart Transplantation , Immunosuppressive Agents/pharmacology , Propylene Glycols/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Combinations , Female , Fingolimod Hydrochloride , Lymphocyte Count , Mice , Mice, Inbred BALB C , Mice, Inbred C3H , Sphingosine/analogs & derivatives , Transplantation, Heterotopic , Transplantation, Homologous
6.
Transpl Immunol ; 8(4): 267-77, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11316070

ABSTRACT

OBJECTIVE: The immunomodulator, FTY720, lowers the peripheral lymphocyte count (PLC) by inducing migration of circulating lymphocytes to secondary lymphoid organs. We investigated the efficacy of mono- vs. combined-FTY720/CsA therapy on graft survival (GS) and on lowering the PLC in a solid organ and a skin graft model, using strains with strong MHC disparity. METHODS: Heterotopic cardiac or tail skin grafting was performed using the DA (RT1a) to Lewis (RT1(1)) rat strain combination. FTY720 was administered as a single daily dose by gavage alone or in combination with subcutaneously delivered CsA. PLC, body weight and drug concentrations were determined on day 7, 28, or the day of rejection. MAIN FINDINGS: In placebo-treated animals the heart and skin allografts rejected after 6 and 8 days. FTY720 delayed rejection of both the solid organ and skin grafts. The maximal effect was achieved at 1 mg x kg(-l) x day(-1) FTY720, resulting in a median survival time (MST) of 14 days for both allotransplants comparable to the effect achieved by 1 mg x kg x day(-1) CsA in both models. In the cardiac graft experiment with CsA co-administration, doses of 0.3 and 1 mg/kg were used. Under these conditions very small doses of FTY720 were effective in maintaining grafts throughout the treatment period. Adding higher FTY720 doses to the 1 mg x kg(-1) x day(-1) CsA was needed to effectively extend the skin GS, e.g. 0.3 mg x kg(-l) x day(-1) FTY720 prolonged GS from 13 to 47.5 days MST, i.e. well beyond the 28 day-treatment period. CsA did not influence the PLC at clinically relevant doses. FTY720 lowered the PLC significantly and dose-dependently, at doses lower than those needed for the prolongation of both cardiac and skin GS with FTY720 monotherapy. In rats with skin grafts the PLC was markedly lowered up to 1 mg x kg(-1) x day(-1) FTY720, whereas, in the heart model, it was lowered up to 0.1 mg x kg(-1) x day(-1). Independently of the graft type, within the combination regimens 0.3 mg x kg(-1) x day(-1) FTY720 achieved a maximal PLC depletion. CONCLUSIONS: Combining FTY720 and CsA was very well tolerated with respect to weight gain and lack of any clinically detectable infections. In the strain combination used FTY720 monotherapy was less effective than previously reported in maintaining grafts. The two-drug regimens extended strikingly the GS for both models. However, the prolongation of the heart GS was smoothly dose-related with FTY720 doses ranging from 0.01 to 1 mg x kg(-1) x day(-1) , whereas, the skin graft prolongation was modest at doses up to 0.1 mg x kg(-1) x day(-1) and remarkably enhanced at 0.3 and 1 mg x kg(-1) x day(-1) FTY720.


Subject(s)
Adjuvants, Immunologic/pharmacology , Cyclosporine/pharmacology , Graft Survival/drug effects , Heart Transplantation/immunology , Immunosuppressive Agents/pharmacology , Propylene Glycols/pharmacology , Skin Transplantation/immunology , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/blood , Adjuvants, Immunologic/therapeutic use , Animals , Body Weight/drug effects , Cyclosporine/administration & dosage , Cyclosporine/blood , Cyclosporine/therapeutic use , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Drug Synergism , Drug Therapy, Combination , Fingolimod Hydrochloride , Graft Rejection/prevention & control , Histocompatibility Antigens/immunology , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Immunosuppressive Agents/therapeutic use , Lymphocyte Count , Male , Models, Animal , Propylene Glycols/administration & dosage , Propylene Glycols/blood , Propylene Glycols/therapeutic use , Rats , Rats, Inbred Lew , Rats, Inbred Strains , Sphingosine/analogs & derivatives
7.
Transpl Immunol ; 8(2): 115-24, 2000 Jun.
Article in English | MEDLINE | ID: mdl-11005317

ABSTRACT

OBJECTIVE: The new immunomodulator 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride (FTY720) lowers the peripheral lymphocyte count (PLC) by inducing migration of circulating lymphocytes to secondary lymphoid organs. This effect is dose-dependent at low (up to 0.1 mg/kg per day) doses in rats. We investigated the correlation between PLC and the later rejection, when FTY720 was combined with RAD. METHODS: Heterotopic cardiac grafting was performed using the DA-Lewis strain combination. FTY720 and RAD were administered as single daily doses by gavage alone and in combination starting 3 days before to 28 days after transplantation. Graft survival was monitored daily by palpation. PLC was determined at 1 and 4 weeks, body weight (BW) weekly. Histologic evaluation of grafted hearts was performed after rejection. MAIN FINDINGS: FTY720 at doses of 0.03, 0.1 and 0.3 mg/kg per day prolonged graft survival dose-dependently from 6 (placebo) to 7, 9.5 and 15 days median survival time (MST). RAD at doses of 0.3, 1 and 3 mg/kg per day delayed rejection to 8.5, 18 and 37.5 days MST. Very small FTY720 doses added to the lower RAD doses were effective in maintaining grafts throughout the treatment period and with normal weight gain, as opposed to regimens with 1 mg/kg or more per day RAD, which resulted in delayed weight gain. FTY720 lowered the PLC significantly and dose-dependently. The PLC correlated well with graft survival [Spearman rank correlation (n = 30, rs = -0.75)]. CONCLUSIONS: Fully effective FTY720 + RAD combination regimens caused no side effects with respect to the rats' general well-being or weight gain and were better tolerated than equiactive RAD monotherapy, suggesting a broader therapeutic window for the combinations. Under the experimental conditions, the PLC decrease showed an interesting correlation with the anti-rejection effects in these two-drug regimens. Thus, in rats the PLC is helpful for monitoring the biological activity of FTY720 at low doses (< 0.1 mg/kg per day), i.e. in the range of the steep part of its dose-response relationship.


Subject(s)
Graft Survival/drug effects , Heart Transplantation/immunology , Immunosuppressive Agents/therapeutic use , Lymphocyte Count , Propylene Glycols/therapeutic use , Sirolimus/analogs & derivatives , Transplantation, Heterotopic , Animals , Body Weight , Drug Therapy, Combination , Everolimus , Fingolimod Hydrochloride , Male , Myocardium/pathology , Rats , Rats, Inbred Lew , Sirolimus/therapeutic use , Sphingosine/analogs & derivatives
8.
NMR Biomed ; 13(6): 329-48, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11002313

ABSTRACT

Critical success factors in solid organ and vascular transplantation are the assessment of graft status/viability as well as stringent monitoring of transplant recipients, preferentially using noninvasive techniques. This review addresses the application of magnetic resonance imaging (MRI) and spectroscopy (MRS) in the field of transplantation. The first section is devoted to the description of the main MR techniques used for monitoring the status of the graft noninvasively. Subsequently, the role of MRI/MRS in the analysis of the viability of organs for transplantation is discussed. Since chronic rejection remains a major difficulty, development of new therapies is still ongoing. Thus, the third part is devoted to the use of MRI/MRS for monitoring graft rejection in animal models of transplantation. This is followed by a discussion of clinical studies of transplantation involving MRI/MRS. Finally, a general appraisal is made on available imaging techniques for the non-invasive characterization of grafts in situ, highlighting the role of MR methods in the field of transplantation.


Subject(s)
Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Models, Animal , Organ Transplantation , Animals , Bone Marrow Transplantation , Fetal Tissue Transplantation , Heart Transplantation , Humans , Kidney Transplantation , Liver Transplantation , Lung Transplantation , Pancreas Transplantation
9.
Transplantation ; 69(12): 2525-30, 2000 Jun 27.
Article in English | MEDLINE | ID: mdl-10910272

ABSTRACT

BACKGROUND: Graft vessel disease (GVD) is an important problem often responsible for late graft loss. The effects of FTY720, an immunomodulator with a novel mechanism of action were investigated in combination with cyclosporine A (CsA) in a carotid artery allograft model. METHODS: A segment of the carotid artery of Lewis rats was replaced by a DA allograft. Seven groups of eight rats were treated for 8 weeks with vehicle (P), CsA 0.3 (C0.3), 1 (C1) or 3 (C3) mg x kg(-1).day(-1) or a combination of CsA 1 with FTY 0.01 (C1F0.01), 0.03 (C1F0.03), and 0.1 (C1F0.1) mg x kg(-1).day(-1). Lumen area was estimated by magnetic resonance imaging, peripheral lymphocyte count and drug concentrations were determined at 1 and 8 weeks. Neointima, media, and lumen area were measured morphometrically. Intimal and adventitial infiltration of mononuclear cells, and medial smooth muscle cells number was assessed using a score. RESULTS: FTY720 did not influence CsA blood concentrations. FTY720 but not CsA decreased the PLC dose dependently. Magnetic resonance imaging revealed that treatment groups have larger lumen size than group P. Histological and morphometric evaluation showed that all aspects of GVD were dose dependently suppressed by treatment and lumen narrowing was prevented. CONCLUSIONS: CsA, at clinically relevant blood levels, suppressed GVD only partly. The addition of FTY720 was well tolerated and completely suppressed GVD development. In vivo lumen size did not correlate with the histologically estimated neointimal thickness.


Subject(s)
Carotid Arteries/transplantation , Carotid Artery Diseases/prevention & control , Cyclosporine/administration & dosage , Immunosuppressive Agents/administration & dosage , Propylene Glycols/administration & dosage , Animals , Carotid Arteries/pathology , Cyclosporine/blood , Fingolimod Hydrochloride , Lymphocyte Count , Magnetic Resonance Imaging , Male , Muscle, Smooth, Vascular/pathology , Propylene Glycols/blood , Rats , Rats, Inbred Lew , Sphingosine/analogs & derivatives
10.
Transplantation ; 65(11): 1489-93, 1998 Jun 15.
Article in English | MEDLINE | ID: mdl-9645808

ABSTRACT

BACKGROUND: The role of T lymphocytes in acute allograft rejection is well established. The involvement of B lymphocytes in this process, however, is more controversial. A series of reports showed that mice without a functional B-cell compartment rejected allografts with the same kinetics as control animals. In rats, however, alloantibodies were found to play a decisive role in allograft rejection. To provide an explanation for the discrepant results, we readdressed the role of B cells and antibodies in mice with disrupted immunoglobulin mu chain genes. The use of cyclosporine (CsA), which strongly suppresses T cells, allowed us to focus specifically on the function of B cells. METHODS: C57BL/6 mice rendered B cell deficient by targeted disruption of the immunoglobulin mu chain gene (referred to as microMT/microMT mice) and microMT/+ control mice with one functional mu chain were heterotopically transplanted with fully MHC-disparate BALB/c hearts. CsA was administered subcutaneously by Alzet osmotic pumps. Normal and immune serum specific for donor hearts was given to assess the role of antibodies in the rejection process. RESULTS: Both B cell-deficient microMT/microMT and heterozygous microMT/+ mice were found to reject transplanted hearts within a similar period of time. In contrast, when T cells were partially suppressed with CsA, graft survival was significantly prolonged in microMT/microMT mice as compared with heterozygous controls. Passive transfer of donor-specific immune serum, obtained from microMT/+ animals rejecting allogeneic hearts, to CsA-treated microMT/microMT mice significantly accelerated allograft rejection as opposed to recipients treated with normal serum. CONCLUSIONS: B lymphocytes and antibodies play an important role in acute allograft rejection particularly when the dominant T-cell compartment is partially suppressed.


Subject(s)
Graft Rejection/immunology , Heart Transplantation/immunology , Isoantibodies/immunology , Animals , B-Lymphocytes/physiology , Cyclosporine/pharmacology , Gene Targeting , Immune Sera/immunology , Immunoglobulin G/genetics , Immunoglobulin mu-Chains/genetics , Immunosuppressive Agents/pharmacology , Mice , Mice, Inbred BALB C/immunology , Mice, Inbred C57BL/genetics , Spleen/cytology , Spleen/immunology , T-Lymphocytes/physiology , Time Factors , Transplantation, Homologous/immunology
11.
Transplantation ; 64(1): 20-7, 1997 Jul 15.
Article in English | MEDLINE | ID: mdl-9233695

ABSTRACT

BACKGROUND: Graft vessel disease is a special form of accelerated arteriosclerosis. Because immunological and nonimmunological factors can contribute to graft vessel disease, we developed a model that enables the study of both factors simultaneously. METHODS: A carotid artery was allografted from DA to Lewis rats, with the excised native artery autografted on the contralateral side. Five groups of six to seven rats were treated for 8 weeks with vehicle (placebo) or cyclosporine (CsA) (0.3, 1, 3, and 10 mg x kg(-1) x day(-1)), which was administered using subcutaneous osmotic minipumps. The carotid lumen area was estimated in vivo at 2, 4, and 8 weeks by magnetic resonance imaging (MRI); CsA blood levels were determined twice. Carotid neointimal thickening and medial and luminal area were measured with histological techniques. RESULTS: MRI showed bulging of the allografts but not autografts. Bulging disappeared over time with narrowing of the allograft lumina estimated by both MRI and histology. Histologically, vehicle-treated animals developed a massive neointima, which was inhibited in a dose-dependent manner by CsA. Autografts remained normal except for minimal subintimal thickening of two of four arteries in the group given the highest dose of CsA. Cellular rejection was detected in the allografts of all but the highest-dose group. The CsA blood levels were similar to those used in man at the two lower doses and about 10-fold higher at the highest dose. CONCLUSIONS: Subintimal thickening did not correlate with in vivo lumen size, a phenomenon that we have previously described for balloon catheter-induced lesions. CsA blood concentrations similar to those used in patients suppressed neointima formation in part, and 10-fold higher concentrations almost completely suppressed neointima formation.


Subject(s)
Carotid Arteries/transplantation , Animals , Body Weight , Carotid Arteries/anatomy & histology , Carotid Arteries/pathology , Cyclosporine/therapeutic use , Graft vs Host Disease/prevention & control , Magnetic Resonance Imaging , Postmortem Changes , Rats , Rats, Inbred Lew , Rats, Inbred Strains , Transplantation Immunology , Transplantation, Autologous/mortality , Transplantation, Autologous/pathology , Transplantation, Homologous/mortality , Transplantation, Homologous/pathology
12.
Cardiovasc Drugs Ther ; 8(2): 235-44, 1994 Apr.
Article in English | MEDLINE | ID: mdl-7918136

ABSTRACT

The effects of the new inotropic agent, SDZ 218-135 [(+)-(S)-4-[3-(4-diphenyl-methyl-1-piperazinyl)-2-hydroxy-propyl]- 6-(2-hydroxyethyl)-5-methyl-1,2,4-triazolo-[1,5-a]pyrimidin-7(4H)-one], were investigated using in vitro and in vivo techniques. In isolated rat atria, SDZ 218-135 elicited a dose-dependent increase in contractile force (+50% at 10 microM), which was paralleled by an increase in functional refractory period. In anesthetized rats SDZ 218-135 enhanced left ventricular (+)dP/dtmax by 100% at 10 mg/kg without influencing heart rate, arterial blood pressure, and cardiac output. In contrast to its predecessor, DPI 201-106, cardiac relaxation remained essentially unimpaired. The positive inotropic action was also maintained in a rabbit model of depressed heart function after myocardial infarction, where SDZ 218-135 increased peak acceleration of blood in the aorta. The prolongation of the effective refractory period in rat atria suggested possible antiarrhythmic effects. Indeed, SDZ 218-135 showed a dose-dependent marked reduction in reperfusion arrhythmias after coronary artery occlusion in rats. This effect was most likely due to a Class III action, since SDZ 218-135 significantly increased action potential duration (+10% at 10 microM/l) of the isolated guinea pig papillary muscle. In conclusion, SDZ 218-135 is a novel positive inotropic agent with an interesting profile of action. It does not impair cardiac relaxation and shows antiarrhythmic effects in a model of reperfusion-induced arrhythmias. The in vivo and in vitro data are consistent with a mechanism of action via sodium channel agonism.


Subject(s)
Cardiotonic Agents/pharmacology , Myocardial Contraction/drug effects , Pyrimidinones/pharmacology , Triazoles/pharmacology , Adenosine Triphosphate/metabolism , Anesthesia , Animals , Arrhythmias, Cardiac/drug therapy , Disease Models, Animal , Electrophysiology , Female , Guinea Pigs , Heart Atria/drug effects , Hemodynamics/drug effects , Isometric Contraction/drug effects , Male , Myocardial Reperfusion Injury/drug therapy , Ovum/drug effects , Papillary Muscles/drug effects , Papillary Muscles/physiology , Phosphodiesterase Inhibitors/pharmacology , Piperazines/pharmacology , Potassium/pharmacology , Propranolol/pharmacology , Rabbits , Rats , Rats, Wistar , Sodium-Potassium-Exchanging ATPase/metabolism
13.
Cardiovasc Res ; 28(2): 215-20, 1994 Feb.
Article in English | MEDLINE | ID: mdl-8143303

ABSTRACT

OBJECTIVE: Both calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are known to diminish the development of intimal thickening after a balloon catheter lesion. It was previously shown that narrowing of carotid artery lumen induced by balloon injury was not influenced by treatment, even though the two ACE inhibitors used inhibited neointimal thickening. The aim of the present study was to include a calcium antagonist as well, in order to investigate whether vasospasm contributes to the persistence of lumen narrowing in ACE inhibitor treated rats after a balloon lesion. METHODS: Six groups of 10 rats were subject to balloon lesion of the left carotid artery. They received spirapril (10 mg.kg-1 x d-1) or isradipine (30 or 100 mg.kg-1 x d-1) or both, given throughout the study in the food. Controls received no drug. Neointimal thickening was measured histologically two weeks after injury. The cross sectional carotid lumen area was measured in vivo by nuclear magnetic resonance imaging, both before and two weeks after balloon injury, and also postmortem by histological techniques. RESULTS: Two weeks after injury, the lumen area of the left carotid artery was significantly reduced following balloon injury, as measured by both techniques. Treatment did not modify the stenosis process as assessed by either method for measuring lumen size. Neointimal thickening, however, was inhibited by between 4% (low dose isradipine) and 59% (combined spirapril + high dose isradipine) in the various treatment groups. CONCLUSIONS: Since calcium antagonist treatment was not able to influence the reduction of lumen size, it is unlikely that the narrowing is due to reversible spasm of the carotid artery in the first two weeks after inducing a balloon lesion. Alternatively, chronic vasospasm of neointimal smooth muscle might not be very sensitive to calcium antagonists.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Calcium Channel Blockers/therapeutic use , Carotid Artery Injuries , Carotid Stenosis/prevention & control , Catheterization/adverse effects , Angioplasty, Balloon, Coronary/adverse effects , Animals , Carotid Artery, Common/pathology , Carotid Stenosis/pathology , Enalapril/analogs & derivatives , Enalapril/therapeutic use , Isradipine/therapeutic use , Magnetic Resonance Spectroscopy , Rats , Rats, Wistar
14.
Blood Press ; 2(4): 322-31, 1993 Dec.
Article in English | MEDLINE | ID: mdl-8173703

ABSTRACT

Five groups of 12 rats were subject to balloon lesion of the left carotid artery and neointimal thickening was measured histologically 2 weeks after injury. Rat groups received either spirapril (3, 10 or 30 mg/kg/day, administered throughout the study in the food), cilazapril (10 mg/kg/day) or placebo. Spirapril caused a dose-dependent inhibition of the neointimal thickening of the rat carotid artery. The degree of inhibition with 10 mg/kg/d spirapril and cilazapril was similar (-44% and -42% respectively). The carotid lumen area was measured in vivo by nuclear magnetic resonance (NMR) imaging both before and 2 weeks after balloon injury and also postmortem by histological techniques. Two weeks after injury, the lumen area of the left carotid artery was significantly reduced following balloon injury, as measured by both techniques. Treatment did not detectably modify this stenosis process despite the use of two independent methods for assessing lumen size, even though neointimal thickening was strongly attenuated by both angiotensin converting enzyme inhibitors. This dissociation between inhibition of neointimal lesion development and decrease of lumen size provides a new view of the role of angiotensin converting enzyme inhibitors in vascular damage situations. Our results suggest that the focus, particularly in clinical studies, on lumen size, may mean that potentially beneficial effects of these drugs on other parts of the vascular wall be overlooked.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Carotid Artery Injuries , Catheterization/adverse effects , Cilazapril/pharmacology , Enalapril/analogs & derivatives , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Carotid Arteries/pathology , Enalapril/pharmacology , Heart Rate/drug effects , Histocytochemistry , Magnetic Resonance Imaging , Rats , Rats, Wistar , Tissue Fixation
15.
J Cardiovasc Pharmacol ; 22(5): 768-75, 1993 Nov.
Article in English | MEDLINE | ID: mdl-7506331

ABSTRACT

Vascular selective calcium antagonists (CAs) show an improved tolerance and a reduced incidence of adverse cardiac effects, especially in treatment of hypertension. The effects of seven well-known CAs on contractions of single isolated rat myocytes were studied and compared with their effects on stimulated 45Ca2+ uptake of rat aortic smooth muscle cells (A7r5 cell line). In the latter test system, the order of potency to inhibit 45Ca2+ uptake was as follows (pIC25, -logM): isradipine (9.2), felodipine (8.7), nifedipine (8.5), nisoldipine (8.5), nicardipine (8.1), verapamil (6.7), and diltiazem (6.5). The potencies for inhibition of ventricular myocyte contraction at 0.5 Hz were (pIC25): isradipine (6.9), nisoldipine (6.7), felodipine (6.6), nicardipine (6.5), nifedipine (6.5), verapamil (5.3), and diltiazem (4.8). Thus, the order of vascular selectivity (i.e., the ratios of IC25 cardiocytes/IC25 A7r5 cells) was: isradipine (184), felodipine (128), nifedipine (107), nisoldipine (63), diltiazem (48), nicardipine (43), and verapamil (23). When ventricular cells were stimulated at 1 Hz, the order of selectivity was changed: Diltiazem was the least selective. Verapamil, diltiazem, and felodipine showed a highly frequency-dependent negative inotropic effect, whereas the effects of the other dihydropyridines were less affected by the frequency of stimulation. CAs show different degrees of vascular selectivity and different frequency-dependent profiles, and vascular selectivities are also dependent on experimental conditions. Selectivity is thus not necessarily related to chemical classes of drugs (e.g., dihydropyridines) or to different binding sites at the channel protein but could instead be due to varying dissociation rates from the respective binding sites at the channel in its different voltage-dependent states.


Subject(s)
Calcium Channel Blockers/pharmacology , Calcium/metabolism , Muscle, Smooth, Vascular/drug effects , Myocardial Contraction/drug effects , Myocardium/metabolism , Animals , Cells, Cultured , Electric Stimulation , Male , Muscle, Smooth, Vascular/metabolism , Rats , Rats, Wistar
16.
J Cardiovasc Pharmacol ; 22(3): 499-505, 1993 Sep.
Article in English | MEDLINE | ID: mdl-7504144

ABSTRACT

Tropisetron (ICS 205-930) is a novel drug that blocks serotonin (5-HT3) receptors and, at higher concentrations, potassium channels. Programmed electrical stimulation (PES) and tracer microspheres were used to investigate antiarrhythmic, systemic, and regional hemodynamic effects in anesthetized rabbits. Tropisetron (0.3, 1, and 3 mg/kg intravenously, i.v.) dose-dependently increased the effective refractory period (ERP) to a first and similarly to a second extrastimulus. The arrhythmias elicited by PES with one and two extrastimuli were suppressed dose dependently. The same doses and a higher dose (6 mg/kg i.v.) were tested for systemic, especially cardiodepressant, and regional hemodynamic activity in a second series of experiments. Doses < or = 3 mg/kg were almost devoid of systemic hemodynamic activity and did not alter the ECG. At the highest dose used (6 mg/kg), cardiodepression caused a decrease in blood pressure (BP), cardiac output (CO), and heart rate (HR) and an increase in central venous pressure (CVP). A selective increase in gastric blood flow was observed, starting at the lowest dose used. The highest cardiodepressant dose reversed this increase and decreased regional myocardial blood flow, especially to the subendocardial layer of the left ventricle, probably by lowering myocardial oxygen consumption. Antiarrhythmic effects thus start at 0.3 mg/kg, and doses < or = 3 mg/kg i.v. did not elicit hemodynamic side effects.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Blood Pressure/drug effects , Cardiac Output/drug effects , Heart Rate/drug effects , Indoles/pharmacology , Animals , Dose-Response Relationship, Drug , Electric Stimulation , Indoles/administration & dosage , Injections, Intravenous , Microspheres , Oxygen Consumption/drug effects , Rabbits , Tropisetron
17.
J Cardiovasc Pharmacol ; 21(6): 937-46, 1993 Jun.
Article in English | MEDLINE | ID: mdl-7687720

ABSTRACT

Structural alterations after myocardial infarction (MI) in rats are usually examined only after death of the experimental animal. Magnetic resonance imaging (MRI) allows repeated and noninvasive measurements of important structural [left ventricular (LV) mass, LV wall thickness, LV chamber radius] as well as function [LV end-systolic and LV end-diastolic volume, stroke volume (SV), ejection fraction (EF)] parameters for a prolonged period. We describe our experience in a series of experiments in rats. Three weeks after MI, infarct size (IS) was determined by MRI and the rats were divided into two groups with equal IS. Three weeks later, treatment with the angiotensin-converting enzyme (ACE) inhibitor spirapril (10 mg/kg in food) or placebo was started. In both groups, the first MRI scan taken before the treatment showed moderately dilated left ventricles and signs of impaired LV function, i.e., an increase in LV end-systolic and end-diastolic volume and decreased EF. After 3-week treatment, no significant differences with respect to heart structure and function were detected as compared with those of untreated animals. Prolonged treatment for 10 weeks with spirapril resulted in significant reduction of LV dilatation, LV mass, and LV end-systolic and end-diastolic volume, which was accompanied by improved EF. Hemodynamic examinations after treatment for 6 months showed, in contrast to control animals, no increase in right ventricular systolic pressure in animals receiving spirapril. Furthermore, histologic examination of perfusion-fixed hearts at the end of the study demonstrated more pronounced LV dilatation in control animals, thus confirming the in vivo MRI data. Delayed treatment with spirapril proved to have beneficial effects on structure and function of infarcted hearts within 10 weeks. Spirapril limited LV dilatation, reduced LV weight and LV end-systolic and end-diastolic volumes, and improved EF.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/pharmacology , Enalapril/analogs & derivatives , Myocardial Infarction/pathology , Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Enalapril/pharmacokinetics , Enalapril/pharmacology , Hemodynamics/drug effects , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Myocardial Infarction/physiopathology , Peptidyl-Dipeptidase A/blood , Perfusion , Rats , Rats, Wistar , Stroke Volume/physiology , Ventricular Function, Left/drug effects
18.
J Cardiovasc Pharmacol ; 21(6): 967-72, 1993 Jun.
Article in English | MEDLINE | ID: mdl-7687724

ABSTRACT

Among antiarrhythmic agents, those belonging to class III are considered most promising. Class III drugs act by prolonging the action potential duration (APD), which increases the effective refractory period (ERP). This effect can be achieved by several different cellular mechanisms. We hypothesized that among other variables the mechanism of action could be important for the propensity of class III agents to have proarrhythmic effects. We investigated the effects of sotalol (a potassium channel blocker) and DPI 201-106 (DPI, an activator of sodium channels) at doses causing the same increase in ERP, using programmed electrical stimulation (PES) in open-chest rabbits. After baseline measurements, three cumulative doses of DPI (0.3, 1, and 3 mg/kg) or sotalol (0.1, 0.3, and 1 mg/kg) or vehicle (placebo) were infused. Before drug administration, PES elicited arrhythmias in 11 of 21 animals. These arrhythmias remained unchanged in the placebo group and decreased dose dependently with sotalol. DPI, however, increased the inducibility of arrhythmias in all animals at the third dose. The two agents differed with respect to their effect on ERP2, measured with a second extrastimulus. In contrast to ERP1, which was prolonged to the same extent by both drugs, ERP2 was prolonged more by sotalol than by DPI. Proarrhythmic effects of sotalol could not be shown in this model. Our results suggest that the cellular mechanism that causes the class III effect is an important factor with respect to the occurrence of proarrhythmic activity.


Subject(s)
Arrhythmias, Cardiac/chemically induced , Piperazines/pharmacology , Sotalol/pharmacology , Animals , Arrhythmias, Cardiac/physiopathology , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Electric Stimulation , Heart Rate/drug effects , Rabbits , Refractory Period, Electrophysiological/drug effects
19.
Cardiovasc Res ; 27(3): 515-9, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8490953

ABSTRACT

OBJECTIVE: The aim was to determine the effect of myocardial hypertrophy on the incidence and severity of arrhythmias following reperfusion after experimental coronary artery occlusion, and to establish if the effect differed between pressure overload hypertrophy and volume overload hypertrophy. METHODS: The experiments were performed in rats. Pressure overload hypertrophy was induced by aortic banding, and volume overload hypertrophy by perforation of the aortic valve. Four weeks after surgery, coronary artery occlusion and reperfusion experiments were performed. RESULTS: Both pressure and volume overloaded hearts exhibited a similar degree of left ventricular hypertrophy of about 45% weight gain compared to control animals. The total number of ventricular premature beats during reperfusion was not significantly increased in either model of hypertrophy. In contrast to volume overload, the incidence of reperfusion induced ventricular fibrillation was significantly increased in pressure overloaded hearts. Furthermore, there was a significant correlation between number of ventricular premature beats and degree of left ventricular hypertrophy, as well as between duration of ventricular tachycardia and degree of hypertrophy in the pressure overloaded group. Such correlations were not observed in hypertrophy due to volume overload. Neither volume nor pressure overload hypertrophy significantly increased mortality from ventricular fibrillation. CONCLUSIONS: An increase in cardiac mass per se does not necessarily aggravate reperfusion arrhythmias. The susceptibility to arrhythmias in this model seems to be critically dependent on the nature of the stimulus triggering left ventricular hypertrophy.


Subject(s)
Arrhythmias, Cardiac/etiology , Coronary Circulation/physiology , Heart Rate/physiology , Hypertrophy, Left Ventricular/physiopathology , Myocardial Reperfusion , Animals , Blood Pressure/physiology , Male , Organ Size , Pressure , Rats , Rats, Wistar , Ventricular Fibrillation/physiopathology , Weight Gain
20.
J Pharmacol Toxicol Methods ; 28(2): 73-7, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1482788

ABSTRACT

Dimension measurements of the right ventricle are difficult to obtain because of its complex geometry, thus we evaluated a method of right ventricular dimension measurements. Crystals were placed on the ventral and dorsal side of the right ventricular free wall, approximately one-fourth of the right ventricular semicircle away from the septum, in the middle of a cranio-caudal axis of the ventricles. The effects of an increased (infusion of 20 mL/kg of 5% glucose for 3 min into seven rabbits), as well as decreased preload (nitroglycerin, 5 micrograms/kg/min i.v. n = 6) were measured and compared with changes during a placebo infusion (n = 6). The change in shortening of the right ventricle wall segment correlated with changes in both atrial natriuretic factor (ANF) plasma concentration (r = 0.89, p < 0.05) and central venous pressure (CVP) (r = 0.94, p < 0.05), respectively. Both these variables are influenced by right ventricular function and dimensions in healthy animals. Dimension measurements obtained across the free wall of the right ventricle appear to reflect right ventricular function well and should be useful in assessing the effects of drugs intended for the treatment of angina pectoris or heart failure.


Subject(s)
Heart Ventricles/diagnostic imaging , Ventricular Function, Right/physiology , Animals , Atrial Natriuretic Factor/blood , Central Venous Pressure/physiology , Hemodynamics , Male , Placebos , Rabbits , Ultrasonography/methods , Ventricular Function, Right/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...